Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
261studies shown
Showing 109-120 of 261
Drug study icon
CompletedEUCTR 2007-003312-65

2 doses of S 90098 (1 and 2mg/day), sublingual formulation for depression

This study is completed in France, in Finland, in Czechia, .... It is testing 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionOther
Countries
France, Finland, Czechia, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
Other study type icon
CompletedEUCTR 2009-014045-92

3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, for depression

This study is completed in France, in Finland, in Czechia, .... 5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, for depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionOther
Countries
France, Finland, Czechia, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
Behavioral study icon
CompletedNCT06677723

High- vs Low-Frequency Exercise for Depression in Adolescents

This summary needs review. Please check the official study record and contact the research team for details.

In France
Why is this study shown?

This study is directly about Depression.

DepressionBehavioralFrom 18 Years to 22 Years
Countries
France
Sponsor
Je Bouge Pour Mon Moral
Condition
Depression
Biological study icon
CompletedNCT00998231

Major Depression and Messenger RNAs

This summary needs review. Please check the official study record and contact the research team for details.

In France
Why is this study shown?

This study is directly about Depression.

DepressionBiologicalOver 18 Years
Countries
France
Sponsor
Assistance Publique Hopitaux De Marseille
Condition
Depression
Drug study icon
CompletedNCT03097133

Intranasal Esketamine for depression

This study is completed in the United States, in France, in Canada, .... It is testing intranasal Esketamine for depression.

In France
Why is this study shown?

This study is directly about Depression.

Depression, SuicidalityDrugA study involving a medication or substance.From 18 Years to 64 Years
Countries
United States, France, Canada, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression, Suicidality
Drug study icon
CompletedNCT03227224

JNJ-42847922 for depression

This study is completed in the United States, in France, in Bulgaria, .... It is testing JNJ-42847922 for depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 70 Years
Countries
United States, France, Bulgaria, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT03185819

3 Fixed Doses of Intranasal Esketamine for depression

This study is completed in the United States, in France, in Belgium, .... It is testing 3 Fixed Doses of Intranasal Esketamine for depression.

In France
Why is this study shown?

This study is directly about Depression.

Depression, SuicidalityDrugFrom 9 Years to 17 Years
Countries
United States, France, Belgium, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression, Suicidality
Drug study icon
CompletedEUCTR 2009-016648-38

Safety and Efficacy of Armodafinil Treatment for depression

This study is completed in France, in Bulgaria, in Spain, .... It is testing safety and Efficacy of Armodafinil Treatment for depression.

In France
Why is this study shown?

This study is directly about Depression.

Depression, BipolarityOther
Countries
France, Bulgaria, Spain, ...
Sponsor
Cephalon, Inc.
Condition
Depression, Bipolarity
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.